Carbon dioxide insufflation reduces the relapse of ulcerative colitis after colonoscopy: A randomized controlled trial.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
04
2023
accepted:
01
08
2023
medline:
21
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
Colonoscopy is necessary for diagnosing and surveilling patients with ulcerative colitis, though it may cause disease flares. Colonoscopy with carbon dioxide (CO2) insufflation decreases abdominal discomfort; however, its effect on exacerbation incidence in ulcerative colitis remains unclear. Therefore, this study aimed to evaluate the colonoscopy effects using CO2 insufflation in patients with ulcerative colitis. Overall, 96 remissive patients with ulcerative colitis (partial Mayo score ≤ 2) who underwent total colonoscopy between March 2015 and December 2019 at Osaka University Hospital were enrolled and blindly randomized to the CO2 (n = 45) and air (n = 51) insufflation group (UMIN-CTR, number: UMIN000018801). The post-procedural abdominal discomfort and the clinical relapse (partial Mayo score ≥ 3) rate within 8 weeks were evaluated. Baseline backgrounds did not differ between the groups. The mean abdominal fullness and pain scores were significantly lower in the CO2 group than in the Air group immediately (p = 0.0003, p = 0.0003) and 30 min (p < 0.0001, p < 0.0001) after colonoscopy. While the overall clinical relapse rate remained unchanged between the groups, the clinical relapse rate at 8 weeks after colonoscopy was significantly lower in the CO2 group than in the Air group in patients not in complete remission (Mayo endoscopic subscore ≥ 1, p = 0.049; or partial Mayo score ≥ 1, p = 0.022). CO2 insufflation can reduce abdominal discomfort in remissive patients with ulcerative colitis and decrease clinical relapse at 8 weeks after colonoscopy for those not in complete remission.
Sections du résumé
BACKGROUND AND AIM
Colonoscopy is necessary for diagnosing and surveilling patients with ulcerative colitis, though it may cause disease flares. Colonoscopy with carbon dioxide (CO2) insufflation decreases abdominal discomfort; however, its effect on exacerbation incidence in ulcerative colitis remains unclear. Therefore, this study aimed to evaluate the colonoscopy effects using CO2 insufflation in patients with ulcerative colitis.
METHODS
Overall, 96 remissive patients with ulcerative colitis (partial Mayo score ≤ 2) who underwent total colonoscopy between March 2015 and December 2019 at Osaka University Hospital were enrolled and blindly randomized to the CO2 (n = 45) and air (n = 51) insufflation group (UMIN-CTR, number: UMIN000018801). The post-procedural abdominal discomfort and the clinical relapse (partial Mayo score ≥ 3) rate within 8 weeks were evaluated.
RESULTS
Baseline backgrounds did not differ between the groups. The mean abdominal fullness and pain scores were significantly lower in the CO2 group than in the Air group immediately (p = 0.0003, p = 0.0003) and 30 min (p < 0.0001, p < 0.0001) after colonoscopy. While the overall clinical relapse rate remained unchanged between the groups, the clinical relapse rate at 8 weeks after colonoscopy was significantly lower in the CO2 group than in the Air group in patients not in complete remission (Mayo endoscopic subscore ≥ 1, p = 0.049; or partial Mayo score ≥ 1, p = 0.022).
CONCLUSIONS
CO2 insufflation can reduce abdominal discomfort in remissive patients with ulcerative colitis and decrease clinical relapse at 8 weeks after colonoscopy for those not in complete remission.
Identifiants
pubmed: 37590283
doi: 10.1371/journal.pone.0290329
pii: PONE-D-23-12603
pmc: PMC10434883
doi:
Substances chimiques
Carbon Dioxide
142M471B3J
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0290329Informations de copyright
Copyright: © 2023 Otake-Kasamoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Endoscopy. 2005 Aug;37(8):706-9
pubmed: 16032487
J Dig Dis. 2015 Dec;16(12):747-51
pubmed: 26639093
J Clin Med. 2022 Sep 07;11(18):
pubmed: 36142931
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
World J Gastroenterol. 2014 Sep 7;20(33):11505-24
pubmed: 25206258
World J Gastroenterol. 2019 Aug 14;25(30):4148-4157
pubmed: 31435169
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174
Gut. 2004 May;53(5):685-93
pubmed: 15082587
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
J Crohns Colitis. 2011 Jun;5(3):189-95
pubmed: 21575880
J Gastroenterol. 2021 Jun;56(6):489-526
pubmed: 33885977
J Gastroenterol Hepatol. 2020 Mar;35(3):380-389
pubmed: 31596960
Surg Laparosc Endosc Percutan Tech. 2016 Apr;26(2):102-16
pubmed: 26841319
Gastrointest Endosc. 1984 Apr;30(2):68-70
pubmed: 6425108
Dig Endosc. 2016 Apr;28(3):260-5
pubmed: 26096182
World J Gastroenterol. 2009 Mar 28;15(12):1475-9
pubmed: 19322921
J Clin Gastroenterol. 2018 Nov/Dec;52(10):e92-e96
pubmed: 29521725
Eur J Gastroenterol Hepatol. 2017 Mar;29(3):355-359
pubmed: 27845950
Inflamm Bowel Dis. 2007 Jan;13(1):12-8
pubmed: 17206634
World J Gastroenterol. 2014 Nov 28;20(44):16389-97
pubmed: 25469007
Gut. 2002 May;50(5):604-7
pubmed: 11950803
Dis Colon Rectum. 2003 Mar;46(3):322-6
pubmed: 12626906